NNT to prevent 1 death from any cause
Aspirin for secondary prevention: 333
Spironolactone for HFrEF: 9
If discharging a CAD patient without aspirin sounds crazy, then what does that say about discharging a HFrEF patient without an MRA?
On Natural History study of stenosis progression: Nationwide study of 248 736 patients with 2 661 245 coronary artery segments with <50% luminal stenosis, progression to ≥50% luminal stenosis within 15 years occurred in 2.6% of segments, incidence rate 1.45/1000 segment/years.
Current indications of direct oral anticoagulants in Europe, based on instructions for use. To date, there are four indications for dabigatran, six for rivaroxaban, three for apixaban, two for edoxaban, none for betrixaban.
With the evidence generated so far, we may safely conclude that PCI does not improve survival in patients with SIHD. PCI remains key in ACS, and for the improvement of PROMs in consideration of patient compliance and wishes in relation to the intensity of anti-anginals. #TCT2022
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison | Journal of the American College of Cardiology https://t.co/SQ3L2UgiNj
Great to know that the expensive 4-drug HFrEF treatment combo ARNI, BB, MRA, SGLTi that is unaffordable for so many patients is no better that the cheap 3-drug combo ACEi, BB, MRA for mortality, CV mortality, or CV mortality/HF hospitalization.
https://t.co/Hq44qB0Me7
Le boson de Higgs fut détecté pour la première fois en 2012, 48 ans après la prédiction de son existence par une poignée de théoriciens. Il me fut demandé il y a trois ans de raconter son histoire, au tableau noir et avec une simple craie... https://t.co/Zs930mYPkj via @YouTube